"Pharmacogenetics of NSAIDs: Using CYP2C9 Genotype to Guide Treatment"
Non-steroidal anti-inflammatory drugs (NSAIDs) are some of the most commonly used drugs worldwide, but have the potential to cause serious gastrointestinal, renal, and cardiovascular adverse events. Several drugs in this class are metabolized by CYP2C9, and polymorphisms in this enzyme that alter NSAID clearance may affect safety. This talk will summarize evidence supporting the association between CYP2C9 polymorphisms and NSAID exposure and discuss the recently published CPIC guidelines for usingCYP2C9 genotype to guide NSAID therapy.
Deadline for abstracts has been extended to 14 Sept.
"Pharmacogenetics of Antidepressants in Pediatric Patients with Anxiety and Depression"
Dr. Ramsey is the Co-Director of the Genetic Pharmacology Service at Cincinnati Children’s Hospital Medical Center, which offers pharmacogenetic tests to patients and provides interpretation of results. She will present on the retrospective studies of pediatric patients with pharmacogenetic test results that were treated with antidepressants. Her lab found that pharmacogenetic phenotypes were associated with response, tolerability, and length of hospitalization in children with anxiety and/or depression treated with escitalopram, sertraline, and fluoxetine. They also performed pharmacokinetic modeling of escitalopram and sertraline based on CYP2C19 phenotypes to predict doses that would provide equivalent exposure across CYP2C19 phenotypes.
"Human Genetics and Drug Discovery"
Robert Plenge, MD, PhD
Sr. Vice President - Research & Early Development
Bristol Myers Squibb
Copyright © 2020 the Pharmacogenomics Research Network. All Rights Reserved.
Follow us on